Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 155

1.

Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?

Cazzaniga ME, Biganzoli L, Cortesi L, De Placido S, Donadio M, Fabi A, Ferro A, Generali D, Lorusso V, Milani A, Montagna E, Munzone E, Orlando L, Pizzuti L, Simoncini E, Zamagni C, Pappagallo GL; “Metronomic Chemotherapy in Advanced Breast Cancer” Study Group.

Onco Targets Ther. 2019 Apr 23;12:2989-2997. doi: 10.2147/OTT.S189163. eCollection 2019.

2.

Avelumab in gastric cancer.

Roviello G, D'Angelo A, Generali D, Pittacolo M, Ganzinelli M, Iezzi G, Manzini N, Sobhani N.

Immunotherapy. 2019 Jun;11(9):759-768. doi: 10.2217/imt-2019-0011. Epub 2019 May 6.

PMID:
31060469
3.

Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer.

Sobhani N, D'Angelo A, Pittacolo M, Roviello G, Miccoli A, Corona SP, Bernocchi O, Generali D, Otto T.

Cells. 2019 Apr 6;8(4). pii: E321. doi: 10.3390/cells8040321. Review.

4.

New-Generation Hormone Therapies in Nonmetastatic Castration-Resistant Prostate Cancer: Why, Who, When.

Roviello G, Generali D.

Clin Genitourin Cancer. 2019 Feb 6. pii: S1558-7673(18)30797-3. doi: 10.1016/j.clgc.2019.01.020. [Epub ahead of print] No abstract available.

PMID:
30827924
5.

Optimal primary end point in Phase II trials of immune checkpoint inhibitors for advanced solid cancers: an evolving issue.

Roviello G, Generali D, Ianza A.

Immunotherapy. 2019 Apr;11(5):365-368. doi: 10.2217/imt-2018-0204. No abstract available.

6.

The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper.

Cristofanilli M, Pierga JY, Reuben J, Rademaker A, Davis AA, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Giuliano M, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, De Mattos-Arruda L, Ignatiadis M, Cabel L, van Laere SJ, Meier-Stiegen F, Sandri MT, Vidal-Martinez J, Politaki E, Consoli F, Generali D, Cappelletti MR, Diaz-Rubio E, Krell J, Dawson SJ, Raimondi C, Rutten A, Janni W, Munzone E, Carañana V, Agelaki S, Almici C, Dirix L, Solomayer EF, Zorzino L, Darrigues L, Reis-Filho JS, Gerratana L, Michiels S, Bidard FC, Pantel K.

Crit Rev Oncol Hematol. 2019 Feb;134:39-45. doi: 10.1016/j.critrevonc.2018.12.004. Epub 2018 Dec 19. Review.

PMID:
30771872
7.

Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer.

Sobhani N, Generali D, Zanconati F, Bortul M, Scaggiante B.

World J Clin Oncol. 2018 Dec 20;9(8):172-179. doi: 10.5306/wjco.v9.i8.172.

8.

Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study.

Cazzaniga M, Verusio C, Ciccarese M, Fumagalli A, Sartori D, Valerio MR, Airoldi M, Moretti G, Ficorella C, Arcangeli V, Diodati L, Zambelli A, Febbraro A, Generali D, Pistelli M, Garrone O, Musolino A, Vici P, Maur M, Mentuccia L, La Verde N, Bianchi G, Artale S, Blasi L, Piezzo M, Atzori F, Turletti A, Benedetto C, Cursano MC, Fabi A, Gebbia V, Schirone A, Palumbo R, Ferzi A, Frassoldati A, Scavelli C, Clivio L, Torri V.

Oncotarget. 2018 Nov 30;9(94):36720-36721. doi: 10.18632/oncotarget.26431. eCollection 2018 Nov 30.

9.

Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit.

Triulzi T, Regondi V, De Cecco L, Cappelletti MR, Di Modica M, Paolini B, Lollini PL, Di Cosimo S, Sfondrini L, Generali D, Tagliabue E.

Br J Cancer. 2018 Dec;119(12):1487-1494. doi: 10.1038/s41416-018-0318-0. Epub 2018 Nov 27.

10.

Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study.

Cazzaniga M, Verusio C, Ciccarese M, Fumagalli A, Sartori D, Valerio MR, Airoldi M, Moretti G, Ficorella C, Arcangeli V, Diodati L, Zambelli A, Febbraro A, Generali D, Pistelli M, Garrone O, Musolino A, Vici P, Maur M, Mentuccia L, La Verde N, Bianchi G, Artale S, Blasi L, Piezzo M, Atzori F, Turletti A, Benedetto C, Cursano MC, Fabi A, Gebbia V, Schirone A, Palumbo R, Ferzi A, Frassoldati A, Scavelli C, Clivio L, Torri On Behalf Of The Eva Study Group V.

Oncotarget. 2018 Oct 2;9(77):34639-34640. doi: 10.18632/oncotarget.26213. eCollection 2018 Oct 2.

11.

Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡.

Conte P, Frassoldati A, Bisagni G, Brandes AA, Donadio M, Garrone O, Piacentini F, Cavanna L, Giotta F, Aieta M, Gebbia V, Molino A, Musolino A, Ferro A, Maltoni R, Danese S, Zamagni C, Rimanti A, Cagossi K, Russo A, Pronzato P, Giovanardi F, Moretti G, Lombardo L, Schirone A, Beano A, Amaducci L, Bajardi EA, Vicini R, Balduzzi S, D'Amico R, Guarneri V; Reader study level-I and level-II Groups .

Ann Oncol. 2018 Dec 1;29(12):2328-2333. doi: 10.1093/annonc/mdy414.

PMID:
30219886
12.

Pertuzumab therapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer.

Roviello G, Generali D.

Lancet Oncol. 2018 Oct;19(10):1270-1272. doi: 10.1016/S1470-2045(18)30512-6. Epub 2018 Sep 11. No abstract available.

PMID:
30217673
13.

Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study.

Cazzaniga M, Verusio C, Ciccarese M, Fumagalli A, Sartori D, Ancona C, Airoldi M, Moretti G, Ficorella C, Arcangeli V, Diodati L, Zambelli A, Febbraro A, Generali D, Pistelli M, Garrone O, Musolino A, Vici P, Maur M, Mentuccia L, La Verde N, Bianchi G, Artale S, Blasi L, Piezzo M, Atzori F, Turletti A, Benedetto C, Cursano MC, Fabi A, Gebbia V, Schirone A, Palumbo R, Ferzi A, Frassoldati A, Scavelli C, Clivio L, Torri On Behalf Of The Eva Study Group V.

Oncotarget. 2018 Aug 7;9(61):31877-31887. doi: 10.18632/oncotarget.25874. eCollection 2018 Aug 7. Erratum in: Oncotarget. 2018 Oct 2;9(77):34639-34640. Oncotarget. 2018 Nov 30;9(94):36720-36721.

14.

Lower urinary tract infections from external beam radiation therapy in prostate cancer: A single institution experience.

Roviello G, Generali D, Aieta M, Bonetta A.

Rep Pract Oncol Radiother. 2018 Jul-Aug;23(4):298-299. doi: 10.1016/j.rpor.2018.06.001. Epub 2018 Jul 17.

PMID:
30100818
15.

Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer.

Sobhani N, Generali D, D'Angelo A, Aieta M, Roviello G.

Invest New Drugs. 2018 Dec;36(6):1133-1137. doi: 10.1007/s10637-018-0653-2. Epub 2018 Aug 7. Review.

PMID:
30083960
16.

Familial aggregation of gastric cancer with microsatellite instability.

Polom K, Marrelli D, Voglino C, Roviello G, De Franco L, Vindigni C, Generali D, Roviello F.

Acta Chir Belg. 2018 Oct;118(5):287-293. doi: 10.1080/00015458.2017.1379789. Epub 2018 Aug 3.

PMID:
30071769
17.

Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer.

Sobhani N, Ianza A, D'Angelo A, Roviello G, Giudici F, Bortul M, Zanconati F, Bottin C, Generali D.

Cells. 2018 Jul 15;7(7). pii: E76. doi: 10.3390/cells7070076. Review.

18.

PIK3CA mutation in gastric cancer and the role of microsatellite instability status in mutations of exons 9 and 20 of the PIK3CA gene.

Polom K, Marrelli D, Roviello G, Pascale V, Voglino C, Vindigni C, Generali D, Roviello F.

Adv Clin Exp Med. 2018 Jul;27(7):963-969. doi: 10.17219/acem/70795.

19.

Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts.

Guffanti F, Fratelli M, Ganzinelli M, Bolis M, Ricci F, Bizzaro F, Chilà R, Sina FP, Fruscio R, Lupia M, Cavallaro U, Cappelletti MR, Generali D, Giavazzi R, Damia G.

Oncotarget. 2018 May 15;9(37):24707-24717. doi: 10.18632/oncotarget.25185. eCollection 2018 May 15.

20.

Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer.

Roviello G, Corona SP, Multari AG, Paganini G, Chiriacò G, Conca R, Petrioli R, Generali D, Rosellini P, Aieta M.

Oncotarget. 2018 Apr 27;9(32):22332-22339. doi: 10.18632/oncotarget.24900. eCollection 2018 Apr 27.

Supplemental Content

Loading ...
Support Center